IBS-C vs IBS-D Treatment: Why Subtype Changes the Plan

If you have been diagnosed with IBS, you have probably been told it comes in subtypes: IBS-C, IBS-D, IBS-M, and IBS-U. What you may not have been told is how much the treatment plan changes between them. The dietary priorities differ. The first-line drug toolkits barely overlap. Even the way you measure whether treatment is working differs by subtype, because the symptoms that improve first are not the same. This guide walks through the subtype distinctions in clinical detail, what works and what fails for each, where brain-gut therapies fit (the answer is more interesting than "they help everyone"), and what to do when your subtype shifts on you mid-treatment.

The Rome IV criteria, the international diagnostic standard for functional bowel disorders, do not stop at the diagnosis of IBS. They go a step further and require classification into a subtype based on the predominant stool form during symptom days. The subtypes are IBS-C (constipation predominant), IBS-D (diarrhea predominant), IBS-M (mixed), and IBS-U (unsubtyped, when the pattern does not fit cleanly into any of the others). The classification uses the Bristol Stool Form Scale, with stool types 1 and 2 counting as constipation-pattern stools and types 6 and 7 counting as diarrhea-pattern stools. The thresholds are based on what proportion of bowel movements during symptom days falls into each category.

This subtype information is not paperwork. It is the variable that decides which dietary structure makes sense, which first-line medication to reach for, and which symptoms you measure improvement against. A patient who walks into a clinic and says only "I have IBS" without subtype information leaves the prescriber doing one of two things: asking the questions to determine the subtype before doing anything useful, or guessing. Neither is a good use of an appointment slot. For the depth on the diagnostic criteria themselves and how they handle subtype assignment, the page on the diagnostic criteria including subtype rules is the most thorough reference on this site.

The mechanisms overlap, but the dominant drivers diverge

IBS-C and IBS-D share a substantial chunk of underlying biology. Both involve some degree of visceral hypersensitivity, where normal gut signals are amplified into conscious symptoms. Both involve some component of altered brain-gut signalling. Both can include microbiome shifts, low-grade immune activation in a subset of patients, and dietary triggering. What differs is which mechanisms dominate the clinical picture.

In IBS-C, the dominant biology tends to be slowed colonic transit, retained stool causing distension and pain, and a heavier bloating burden. The bloating in IBS-C is often the symptom patients describe as most disabling, sometimes more than the constipation itself. In IBS-D, the dominant biology tends to be faster colonic transit, exaggerated gastrocolic reflex, urgency, and post-meal evacuation events. The pain pattern is often relief-after-bowel-movement rather than the pre-bowel-movement cramping characteristic of IBS-C.

These mechanism differences are why treating IBS-C with IBS-D approaches (or the reverse) often makes things worse rather than helping. Loperamide in an IBS-C patient produces severe constipation. A secretagogue in an IBS-D patient produces an unmanageable week. Aggressive fibre supplementation can worsen both, but worsens IBS-D much faster. The cost of mismatched mechanism is paid in real symptoms, often within days.

IBS-M is its own treatment-planning challenge

The mixed subtype, IBS-M, is the most clinically frustrating of the four because it requires a strategy that handles both directions without leaning too hard on tools that flip the patient toward the opposite pole. Standing-dose IBS-D medications in an IBS-M patient often trigger the constipation phase. Standing-dose IBS-C medications often trigger the diarrhea phase. This is why IBS-M patients often end up on as-needed pharmacological strategies plus a foundational layer of brain-gut therapy and dietary structure that does not require flipping every week. Honest framing matters here: most IBS patients have at least some mixed component, even if they identify as "IBS-D" or "IBS-C" based on the dominant pattern. The strict Rome IV thresholds capture only the patients whose mixed pattern crosses the 25% bar in both directions.

IBS-C is defined under Rome IV by a stool pattern in which more than 25% of bowel movements during symptom days are hard or lumpy (Bristol types 1 and 2) and less than 25% are loose or watery. Patients often describe straining, a sense of incomplete evacuation, infrequent bowel movements (sometimes only two or three per week), abdominal discomfort that builds through the day, and bloating that gets noticeably worse in the evening. The pain pattern in IBS-C tends to be a pre-bowel-movement cramping that improves, sometimes substantially, after evacuation. This is the opposite of what many people assume IBS pain looks like, and it is a useful clue when patients are unsure which subtype they belong to.

The bloating burden is heavier in IBS-C

Bloating in IBS-C is often the dominant symptom from the patient's perspective, sometimes more than the constipation itself. The mechanism involves retained stool in the colon producing distension, gas accumulation behind the slowed transit, and abdominal wall and diaphragmatic responses (the abdomino-phrenic dyssynergia pattern) that produce visible distension even when the gas volume itself has not increased dramatically. Patients describe waking with a flat stomach and ending the day looking pregnant. Skirts and waistbands that fit at breakfast no longer fit at dinner. This is real physiology, not perception. For the deeper mechanism explanation including the abdomino-phrenic dyssynergia component, the page on the bloating mechanism overlap with IBS-C covers the territory in detail.

Slow colonic transit is the dominant motility picture

In IBS-C, the dominant motility pattern is slowed colonic transit, particularly through the descending and sigmoid colon. The slowing is partial, not absolute, and it is functional rather than structural (no anatomical obstruction). The practical consequence is longer dwell time of stool in the colon, more water reabsorption (which dries the stool and makes it harder), and a higher likelihood of straining and incomplete evacuation. Some IBS-C patients also have an outlet dysfunction component, where the pelvic floor coordination during defecation is impaired (dyssynergic defecation), which adds a separate mechanism on top of the slow transit. Identifying the outlet component matters because it responds to pelvic floor physiotherapy and biofeedback rather than to laxatives, and missing it leads to escalating laxative doses without corresponding improvement.

Common patient experience patterns

The classic IBS-C presentation involves bowel movements every 2 to 4 days, hard or pellet-like stools, abdominal cramping that builds in the afternoon and evening, bloating that progresses through the day, and a sense that "everything backs up" for several days followed by a partial release. Many patients describe a cyclic pattern where they push through several days of buildup, eventually have a partial bowel movement that does not feel complete, and then start the cycle again. Mornings may be relatively calm in IBS-C, with symptoms accumulating later. This is the opposite of the IBS-D pattern, where mornings are often the worst window. Recognising your own daily symptom timing is a useful diagnostic clue when subtype is uncertain.

The trigger profile in IBS-C is heavier on the lifestyle and structural side: low fluid intake, low fibre intake (especially low soluble fibre), sedentary days, disrupted toileting routines (long stretches without using the bathroom when the urge appears), and certain medications (opioids, anticholinergics, some antidepressants, calcium-containing antacids). FODMAPs can still trigger discomfort and bloating in IBS-C, but the pattern is usually slower-acting and more bloating-driven than the rapid urgency many IBS-D patients experience.

IBS-D is defined under Rome IV by a stool pattern in which more than 25% of bowel movements during symptom days are loose or watery (Bristol types 6 and 7) and less than 25% are hard or lumpy. Patients describe urgency that is hard to defer, often multiple bowel movements within the first few hours of waking, post-meal evacuation rushes (especially after breakfast or after fatty meals), and a pain pattern that is typically cramping with urgency, often relieved (sometimes dramatically) after the bowel movement. Many IBS-D patients organise their lives around bathroom proximity, planning routes by available restrooms, avoiding morning meetings, and limiting food intake before known high-pressure events.

Faster transit is the dominant motility pattern

The motility picture in IBS-D is the inverse of IBS-C. Colonic transit is faster than normal, with reduced dwell time, less water reabsorption, and softer or watery stools as a result. The gastrocolic reflex (the normal physiological response that increases colonic motility after a meal arrives in the stomach) is often exaggerated in IBS-D, which is why post-meal urgency is so common in this subtype. The combination of accelerated baseline transit and an exaggerated postprandial response produces the classic IBS-D pattern of multiple bowel movements clustered in the first half of the day, often with a relatively quiet afternoon and evening once the morning rush is over.

Bile acid malabsorption is a frequently missed driver

One of the most under-diagnosed contributors to IBS-D is bile acid malabsorption (BAM). Bile acids are produced in the liver, secreted into the small intestine to aid fat digestion, and normally reabsorbed almost completely in the terminal ileum. When that reabsorption is incomplete (which happens in a subset of IBS-D patients without obvious cause, and more commonly after ileal resection or in inflammatory bowel disease), excess bile acids reach the colon where they act as a powerful secretagogue, drawing water into the lumen and triggering rapid transit. The clinical picture looks identical to other forms of IBS-D, which is why it is so often missed.

Estimates from the gastroenterology literature suggest BAM may account for as much as a quarter of patients carrying an IBS-D label, though the proportion varies by population and diagnostic threshold. Diagnostic options include the SeHCAT scan (where available, mainly in the UK and parts of Europe), serum 7-alpha-hydroxy-4-cholesten-3-one (C4) testing, fecal bile acid measurement, and a therapeutic trial of a bile acid sequestrant such as cholestyramine or colesevelam. The therapeutic trial is the most accessible option in Canadian practice. If your IBS-D has not responded well to standard treatment and the pattern includes worse symptoms after fatty meals, raising BAM with your gastroenterologist is reasonable.

Common patient experience patterns

The classic IBS-D presentation involves multiple bowel movements per day, often clustered in the morning, urgency that interferes with daily activities, post-meal evacuation pressure (especially after breakfast or fatty meals), abdominal cramping that is relieved by passage of stool, and significant anxiety about being far from a bathroom. Sleep is usually preserved (true nocturnal diarrhea is a red flag for organic disease, not IBS). Mucus in the stool is reasonably common in IBS-D and is not in itself a sign of inflammatory disease. Blood in the stool is not consistent with IBS-D and requires investigation.

The trigger profile in IBS-D is broader and faster-acting than in IBS-C. Caffeine, alcohol, fatty meals, large meals, certain FODMAPs (fructans in particular for many patients), artificial sweeteners (sorbitol, mannitol), and acute stress are common triggers. The stress response in IBS-D often produces a noticeable urgency within minutes to an hour, which is one of the reasons IBS-D is so commonly described as a "stress condition" even though stress is one of many drivers rather than the only one. For broader context on what drives IBS in general, the page on the broader IBS mechanism overview walks through the multifactorial picture that applies across subtypes.

Diet is where the IBS-C and IBS-D paths most visibly diverge for patients managing the condition day to day. The same food can be a relief food in one subtype and a trigger food in the other. The same dietary framework (low-FODMAP being the prime example) needs different setup and different priorities depending on subtype. This section walks through the main dietary axes and how they differ.

Low-FODMAP works for both, but the setup differs

The low-FODMAP diet is the most evidence-supported dietary intervention in IBS, with response rates in the 50 to 70% range across multiple trials. It works for both IBS-C and IBS-D, but the setup needs different attention for each. The standard elimination phase removes high-FODMAP foods for 4 to 6 weeks, followed by a structured reintroduction to identify individual triggers, ending with a personalised long-term diet. For IBS-D, the elimination phase often produces noticeable improvement within the first week, with reduced bloating, fewer urgency episodes, and firmer stools. The reintroduction phase focuses on pinpointing which specific FODMAP categories are personal triggers.

For IBS-C, the setup is more delicate. The standard elimination phase is naturally lower in fibre because so many high-FODMAP foods are also high-fibre staples (wheat, onions, garlic, certain legumes, certain fruits). Acutely reducing fibre while you have constipation can worsen the constipation. The fix is to deliberately pair the elimination phase with low-FODMAP fibre sources (oats, kiwifruit, berries, certain seeds, low-FODMAP whole grains) and to maintain or increase fluid intake to around 2 to 2.5 litres per day. For IBS-C the reintroduction priority is also different: prioritise reintroducing the high-volume fermenters (legumes, certain grains, certain fruits) early, because these tend to provide the substrate for the short-chain fatty acids that support normal motility. For a head-to-head perspective on the dietary intervention versus brain-gut therapy comparison that has direct relevance to FODMAP for both subtypes, the dedicated comparison page on this site goes deeper.

Soluble fibre helps IBS-C, mixed for IBS-D

Soluble fibre (psyllium, oat fibre, partially hydrolysed guar gum, certain pectins) is one of the most useful dietary tools in IBS-C. It softens stool, increases stool bulk, draws water into the colon, and improves transit. Psyllium specifically has the best trial evidence in IBS, with reduction in pain and improvement in stool form across multiple studies. The standard starting dose is 5 grams per day, titrated up to 10 to 15 grams over 2 to 4 weeks, taken with adequate fluid. For IBS-D the picture is more mixed. Soluble fibre helps some IBS-D patients by adding bulk and slowing transit slightly, but worsens others by increasing fermentation gas in patients with sensitive bloating responses. The pragmatic approach in IBS-D is a small starting dose (2 to 3 grams of psyllium per day), assessed over 2 weeks, with discontinuation if bloating worsens.

Insoluble fibre worsens both, especially IBS-D

Insoluble fibre (wheat bran is the canonical example) was once recommended broadly for IBS based on the assumption that "more fibre is better." The evidence has not supported this. Insoluble fibre tends to worsen pain and bloating in both IBS-C and IBS-D, and the worsening is most rapid and dramatic in IBS-D where the added bulk plus fermentation effects amplify urgency and cramping. The current consensus is that wheat bran is one of the few dietary changes IBS patients should generally avoid, regardless of subtype. If you have been told to add bran to your diet for IBS, the recommendation is out of date.

Fluid and electrolyte priorities differ

Fluid intake matters for both subtypes but for different reasons. In IBS-C, adequate fluid (around 2 to 2.5 litres per day for most adults) is necessary for soluble fibre to do its softening work and for slowed colonic transit to not produce overly dry stools. Inadequate fluid plus added fibre produces the worst-case scenario of harder, more painful stools. In IBS-D, fluid replacement is about preventing the dehydration that comes with frequent loose stools. Electrolyte balance becomes the bigger consideration, especially during flare periods. Oral rehydration solutions (the WHO formula or commercial equivalents) are appropriate during severe IBS-D flares. Plain water alone during a multi-day flare can produce relative hyponatraemia in some patients.

The medication picture is where IBS-C and IBS-D are most clearly different toolkits. There is essentially no overlap in the first-line drug list. A medication that is first-line for one subtype is contraindicated or actively harmful in the other. Understanding which class belongs to which subtype is one of the most concrete benefits of knowing your subtype with precision. This section is informational rather than prescriptive. Medication selection, dosing, monitoring, and the workup for alternative diagnoses belong with your physician or gastroenterologist. Use this as a vocabulary list for that conversation.

IBS-C first-line medications

Polyethylene glycol (PEG, brand names include MiraLAX in Canada and the US) is an osmotic laxative that draws water into the colon and softens stool without producing the cramping and dependency profile of stimulant laxatives. It is generally first-line for IBS-C constipation in adult patients, with a strong safety profile across long-term use, no electrolyte disturbance at standard doses, and reasonable tolerability. The standard adult dose is 17 grams per day in 240 mL of water, titrated up or down based on response. Onset of effect is typically 1 to 3 days.

Linaclotide and plecanatide are intestinal secretagogues that activate the guanylate cyclase-C receptor on intestinal epithelial cells, increasing chloride and bicarbonate secretion into the lumen, drawing water with them, and accelerating transit. They have direct evidence for both constipation relief and pain relief in IBS-C, which is one of their advantages over a pure laxative. The pain effect is mediated through reduced visceral hypersensitivity, not just through better stool passage. Common side effect is diarrhea, which is dose-related and usually responds to dose reduction.

Prucalopride is a 5-HT4 receptor agonist (a selective serotonin receptor agonist that enhances colonic motility). It is approved primarily for chronic idiopathic constipation but is used off-label or under specific indications for IBS-C in some jurisdictions. Lubiprostone is another secretagogue acting through chloride channel activation, and tegaserod is another 5-HT4 agonist that has had a more complicated regulatory history.

IBS-D first-line medications

Loperamide is a peripherally-acting opioid receptor agonist that slows intestinal transit and increases water absorption, reducing stool frequency and improving stool form. It is the most commonly used as-needed medication for IBS-D. The recommended dose for IBS is generally lower than the over-the-counter dose used for acute travellers' diarrhea (often 1 to 2 mg before known triggers, rather than 4 mg loading doses). It works well for symptom management but does not address underlying mechanisms, and standing high doses risk constipation rebound.

Antispasmodics (dicyclomine, hyoscine butylbromide, otilonium, mebeverine) are anticholinergic or smooth-muscle-relaxant agents used for cramping and urgency in IBS-D. They have modest evidence for symptom reduction in the short to medium term. Side effects include dry mouth, blurred vision, urinary hesitancy, and constipation, all reflecting their anticholinergic action. They are usually used as-needed or for short standing courses rather than long-term daily medication.

Low-dose tricyclic antidepressants (amitriptyline, nortriptyline, desipramine) at the dose range used for visceral pain modulation (typically 10 to 50 mg at bedtime, well below the antidepressant dose range) have good evidence in IBS-D for pain reduction and urgency reduction. The mechanism is thought to be a combination of central pain modulation and peripheral effects on intestinal transit. Side effects include dry mouth, sedation, and weight gain in some patients. The slow onset (4 to 8 weeks for full effect) and the antidepressant association can make patients hesitant, but the evidence is reasonable enough that this class remains in major IBS guidelines.

Rifaximin is a non-absorbable antibiotic that targets the small intestinal microbiome and has evidence in IBS-D, particularly in patients with a small intestinal bacterial overgrowth (SIBO) component. It is typically used as a 14-day course rather than ongoing therapy. Eluxadoline is a mixed opioid receptor agonist and antagonist used in IBS-D in some jurisdictions, with restricted prescribing because of pancreatitis risk in patients without a gallbladder. Bile acid sequestrants (cholestyramine, colesevelam) are used in IBS-D when bile acid malabsorption is identified or strongly suspected.

Medications useful across both subtypes

A small set of medications has evidence across both subtypes, primarily because they act on the visceral pain layer rather than on motility specifically. Peppermint oil (in enteric-coated capsules to prevent gastric release) has good trial evidence for pain and bloating reduction in both IBS-C and IBS-D, with a favourable safety profile. The standard dose is 180 to 225 mg three times daily, taken before meals. Low-dose tricyclics, while particularly emphasised in IBS-D, also have some evidence in IBS-C at lower doses, again working primarily on visceral pain rather than on motility. SNRIs (duloxetine specifically) have smaller trial evidence in IBS for pain modulation, though the data are less robust than for the tricyclics.

Brain-gut therapies are the part of the IBS toolkit that does not split cleanly along subtype lines, and the reason is mechanistic. Where dietary and pharmacological treatments tend to act on subtype-specific drivers (motility, transit, secretion), brain-gut therapies act on the central pain processing layer and the visceral hypersensitivity that runs through all IBS subtypes. The therapy does not need to know whether you are IBS-C or IBS-D to do its work, because the target is the gut-brain interface itself, not the downstream motility pattern.

Gut-directed hypnotherapy works across subtypes

Gut-directed hypnotherapy (GDH) on the Manchester Protocol is the most studied form of clinical hypnotherapy for IBS. The original outcome data from the Manchester clinic, captured in Miller 2015 (PMID 25736234), showed a 76% response rate in 1,000 consecutive refractory IBS patients, with response defined as at least 50% improvement on a validated symptom score. Crucially for the subtype question, that cohort was unselected: it included IBS-C, IBS-D, and IBS-M presentations together, and the response rates did not differ dramatically by subtype. This is real-world clinic data rather than an RCT, but it is the largest single-clinic case series in the field and the best available evidence on whether GDH effects depend on subtype.

The randomised trial evidence for GDH against the most common dietary intervention comes from Peters 2016 (PMID 27397586), which compared gut-directed hypnotherapy head-to-head against a low-FODMAP diet in IBS patients and found equivalent symptom relief at 6-month follow-up. Both interventions produced significant clinically meaningful improvement, and the two arms did not differ on the primary outcomes. The cost, ongoing-effort, and quality-of-life pictures differ meaningfully between the two: GDH wins on long-term ease (no permanent dietary restriction once the course is complete), while FODMAP wins on rapid initial response in some subtypes, particularly IBS-D where the elimination phase can produce dramatic early relief.

The durability question matters because most IBS interventions, including diet, regress at the 12 to 24 month mark. Hasan 2019 (PMID 30702396) followed IBS patients who had received gut-directed hypnotherapy out to 5 or more years and found 76% maintained their initial symptom improvement at long-term follow-up, compared with 65% in a comparison group receiving medical management without GDH. This is one of the strongest pieces of evidence that GDH effects persist long term, which matters for the cost-benefit conversation when you are weighing a time-limited course of brain-gut therapy against ongoing medication or dietary management. For broader treatment of the GDH approach across subtypes, the page on GDH across subtypes covers the protocol detail, session structure, and what to expect.

CBT for IBS works across subtypes

Cognitive behavioural therapy adapted for IBS (CBT-for-IBS) has the other major brain-gut evidence base. Everitt 2019 (PMID 30765267), the large UK ACTIB randomised trial, showed that CBT delivered by trained therapists produced clinically significant IBS symptom improvement in 71% of patients, and the trial included both telephone-delivered and web-delivered formats. CBT-for-IBS is now a recommended option in NICE and BSG guidelines, alongside GDH, for patients who have not responded sufficiently to first-line dietary and pharmacological management. Like GDH, CBT works through cognitive and behavioural mechanisms that are not subtype-specific, which is why the evidence supports its use across IBS-C, IBS-D, and IBS-M.

Important not to position GDH as "better than CBT" or vice versa. The trial designs differ, the patient fits differ (CBT requires more cognitive engagement and homework; GDH requires comfort with the hypnotic state), and both are valid evidence-based options with overlapping but not identical mechanisms. The honest framing is that they are both first-line brain-gut options, that patient preference and therapist availability are reasonable selection criteria, and that the response rates in the well-conducted trials are broadly similar.

Why brain-gut therapies are subtype-agnostic at the mechanism level

The mechanistic reason brain-gut therapies do not need to be different for IBS-C versus IBS-D is that they target a layer of the disorder that is shared. Visceral hypersensitivity (the amplified processing of normal gut signals into conscious symptoms) is present in all IBS subtypes. Central sensitisation in pain-processing brain regions including the anterior cingulate cortex and insula is documented across subtypes. The cognitive and emotional response to gut symptoms (the catastrophising, the hypervigilance to bowel sensations, the avoidance behaviours) shapes outcomes regardless of whether the underlying motility pattern is fast or slow. Brain-gut therapies intervene at this shared layer, which is why their efficacy does not depend on the downstream motility direction.

What does differ by subtype is which symptoms improve first. IBS-D patients on GDH typically notice urgency reduction and pain reduction earliest. IBS-C patients typically notice pain and bloating reduction first, with stool form normalisation following more slowly. Knowing what to watch for during the early weeks of treatment helps patients calibrate expectations correctly rather than concluding too early that "it's not working" because they were measuring the wrong outcome.

One of the most important and least discussed facts about IBS subtype is that it is not fixed. Longitudinal studies of IBS patients consistently show that a substantial proportion change Rome subtype within a 12-month observation window. The estimates vary depending on the cohort and the diagnostic threshold, but the pattern is reliable: anywhere from a quarter to half of patients shift between IBS-C, IBS-D, IBS-M, and IBS-U over the course of a year. The most common transitions are IBS-D to IBS-M (often when treatment slows transit but does not normalise it), IBS-C to IBS-M (often when laxative regimens are titrated up), and IBS-M to one of the dominant subtypes when one direction takes over.

What drives subtype shift

Several factors drive subtype transitions. Diet changes are common drivers: starting or stopping a low-FODMAP framework, shifting fibre intake, changes in alcohol or caffeine consumption, and travel-related dietary disruptions can all push the dominant pattern in one direction or another. Antibiotic exposure can shift the gut microbiome substantially enough to change subtype, particularly after broad-spectrum antibiotic courses for unrelated infections. Hormonal cycling matters in patients with menstrual cycles, with many reporting a perimenstrual shift toward IBS-D regardless of their baseline subtype. Stress load shifts (job change, bereavement, relationship change) can move patients in either direction depending on their personal stress-gut wiring. Post-infectious episodes (a clear bout of gastroenteritis) can produce a lasting shift, often into an IBS-D or IBS-M pattern that persists long after the infection has resolved.

Treatment effects themselves are a frequent driver. A patient with IBS-D started on a tricyclic at the visceral pain dose often slows enough to drift into an IBS-M pattern. A patient with IBS-C started on a secretagogue may swing into looser stools that meet IBS-M or even IBS-D criteria during the early titration period. These shifts are often expected and manageable, but they need to be recognised so that the treatment plan can be adjusted rather than abandoned.

Why a 6 to 12 month treatment review is reasonable

The combination of natural subtype shifts and treatment-induced shifts is the rationale for building a periodic treatment review into any IBS plan. A reasonable cadence is 6 to 12 months. At each review, the questions are: what is the current dominant stool pattern (with a fresh two-week diary, not memory)? What are the current trigger foods? What medications are being used and at what dose and frequency? How is sleep, stress load, and exercise structure? Has anything new appeared in the last review window?

The answers determine whether the existing plan still fits or needs updating. A common scenario is that a patient who started two years ago as IBS-D, was put on loperamide as needed and a low-FODMAP framework, has gradually drifted into an IBS-C or IBS-M pattern, and is now describing constipation that the original plan does not address. The fix is to back off the loperamide, add a soluble fibre source, possibly add a PEG titration, and to expand the FODMAP list back toward the high-volume fermenters that support normal motility. Without the review, this patient ends up on the wrong toolkit for the current physiology and concludes incorrectly that their IBS is "getting worse" when in fact the treatment is now mismatched to the subtype.

The most useful section to share with your physician is often not the one about what works, but the one about what fails. The failure patterns in IBS treatment are reasonably consistent, and they tend to cluster differently for IBS-C and IBS-D. Recognising the pattern in advance saves months of trial and frustration.

IBS-C failure patterns

The most common IBS-C failure is the high-fibre-without-fluid trap. A patient is told to add fibre, increases bran or psyllium dose without correspondingly increasing fluid, and ends up with worse cramping, harder stools, and an honest belief that fibre "does not work" for them. The fix is the fluid, not abandonment of fibre. The second common failure is stimulant laxative dependency. Senna, bisacodyl, and similar stimulant laxatives produce reliable acute bowel movements but, used daily over years, are associated with a rebound pattern where the colon becomes less responsive to its own peristaltic signals and patients require escalating doses for the same effect. Stimulant laxatives are appropriate as occasional rescue therapy, not as a foundational chronic strategy. Osmotic laxatives like PEG do not have the same dependency profile and are the appropriate first-line for chronic use.

A third IBS-C failure is missing the outlet dysfunction component. Some IBS-C patients have a pelvic floor coordination problem (dyssynergic defecation) on top of the slow transit, and laxative escalation alone never addresses it. The clinical clues are straining, sense of incomplete evacuation, need to manually assist evacuation, and persistent constipation despite generous laxative regimens. The treatment is pelvic floor physiotherapy and biofeedback, not more laxative. If your IBS-C has not responded to conventional laxative escalation, raising the outlet dysfunction question with your physician is reasonable.

IBS-D failure patterns

The most common IBS-D failure is restriction fatigue. Patients identify a list of trigger foods and progressively eliminate everything, ending up on a diet of rice, chicken, and white bread that is nutritionally inadequate, socially isolating, and ultimately unsustainable. Within 6 to 12 months, restriction fatigue produces a binge or rebound, often with a worse symptom flare than what the restriction was avoiding in the first place. The structured low-FODMAP framework with planned reintroduction exists specifically to prevent this trap, but the diet only works if you actually do the reintroduction phase rather than treating elimination as a permanent state.

The second common IBS-D failure is over-using loperamide. As-needed loperamide is appropriate. Daily standing high doses produce a cycle of constipation rebound followed by exaggerated diarrhea when the medication is stopped, mimicking a worsening IBS picture. The fix is dose discipline: use the smallest effective dose, prefer pre-event dosing over standing dosing, and review with your physician if you find yourself needing it daily for more than a few weeks.

A third IBS-D failure is missing bile acid malabsorption. As discussed in the IBS-D section above, BAM may account for a substantial proportion of patients carrying the IBS-D label, and standard IBS treatment does not address it. If your IBS-D has not responded well, especially with a fatty-meal trigger pattern, raising BAM with your gastroenterologist is the right move.

Failures common to both subtypes

The single most common cross-subtype failure is what we have been emphasising throughout this page: the right treatment applied to the wrong subtype. A patient labelled IBS-D who actually has IBS-C with overflow incontinence will get worse on loperamide. A patient labelled IBS-C who actually has IBS-M with intermittent looseness will swing into severe diarrhea on a secretagogue. The audit is straightforward: a fresh two-week stool diary, an honest reassessment of the dominant pattern, and a willingness to update the working diagnosis if the data have changed. This single discipline catches a remarkable proportion of treatment failures that look like "the medication stopped working" but are actually "the patient is no longer the subtype the medication was prescribed for."

A second cross-subtype failure is treating IBS as a purely peripheral disorder and ignoring the brain-gut layer. Patients who go through every available diet and every available medication without ever engaging the visceral hypersensitivity component often plateau at partial response and conclude that nothing works for their IBS. The honest reframe is that a layered approach (subtype-appropriate dietary structure plus subtype-appropriate medication as needed plus a brain-gut therapy course) consistently outperforms any single-modality approach in my hypnotherapy practice and in trials.